Oruka's ORKA-001: Owning the Ultra-Long-Dose End of Psoriasis
Oruka Therapeutics (ORKA) is a clinical-stage biotech that looks mispriced given Phase 2 durability data for ORKA-001 and a commercial build underway. The market for biologic psoriasis drugs is polarizing into frequent-dosing incumbents and a few ultra-long-duration challengers; ORKA-001 sits at the high-return end of that barbell. This trade idea …